ID

29196

Description

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01012037

Link

https://clinicaltrials.gov/show/NCT01012037

Keywords

Versions (1)
  1. 3/6/18 3/6/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

March 6, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Diabetes Mellitus, Type 2 NCT01012037

English

Eligibility Diabetes Mellitus, Type 2 NCT01012037

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. diagnosis of type 2 diabetes mellitus.
Description

Diabetes Mellitus, Non-Insulin-Dependent

Data type

boolean

Alias
UMLS CUI [1]
C0011860
2. current treatment with metformin alone (>/= 1500 mg or maximally tolerated dose) or metformin plus 1 other antidiabetic drug. metformin must be administered in twice daily dosing regimen. patients taking metformin three times daily can be included if posology is switched to twice daily and total daily dose is maintained.
Description

Metformin Dose Frequency | Antidiabetics Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0439603
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1265611
3. glycosylated haemoglobin (hba1c) is between 7.0% - 10.0%.
Description

Glucohemoglobin measurement

Data type

boolean

Alias
UMLS CUI [1]
C0202054
4. body mass index (bmi) </=45 kg/m2.
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. treatment with extended release metformin.
Description

Metformin Extended Release

Data type

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C1707968
2. uncontrolled hyperglycaemia (fasting plasma glucose > 240 mg/dl or 13.3 mmol/l).
Description

Hyperglycemia Uncontrolled | Plasma fasting glucose measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C0020456
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0583513
3. myocardial infarction (mi), stroke or transient ischaemic attack (tia) within 6 months prior to informed consent.
Description

Myocardial Infarction | Cerebrovascular accident | Transient Ischemic Attack

Data type

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C0038454
UMLS CUI [3]
C0007787
4. impaired hepatic or renal function, or gastric bypass surgery.
Description

Liver Dysfunction | Renal Insufficiency | Gastric Bypass

Data type

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C1565489
UMLS CUI [3]
C0017125
5. treatment with glitazones, glucagon like peptide-1 (glp-1) analogues/mimetics, antiobesity agents, or insulin within 3 months of informed consent.
Description

Thiazolidinediones | GLP-1 Mimetics | Anti-Obesity Agents | Insulin

Data type

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2]
C3273809
UMLS CUI [3]
C0376607
UMLS CUI [4]
C0021641
6. current treatment with systemic steroids or change in dosage of thyroid hormones.
Description

Systemic steroids | Thyroid Hormones Dosage Change

Data type

boolean

Alias
UMLS CUI [1]
C2825233
UMLS CUI [2,1]
C0040135
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0392747
7. alcohol or drug abuse within 3 months of informed consent.
Description

Substance Use Disorders

Data type

boolean

Alias
UMLS CUI [1]
C0038586
8. participation in another trial with investigational drug within 2 months prior to informed consent.
Description

Study Subject Participation Status | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
9. pre-menopausal women who are nursing, pregnant or not practicing an acceptable method of birth control.
Description

Premenopausal state | Breast Feeding | Pregnancy | Contraceptive methods Absent

Data type

boolean

Alias
UMLS CUI [1]
C0232969
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032961
UMLS CUI [4,1]
C0700589
UMLS CUI [4,2]
C0332197
Back to the top of the page

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT01012037

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
1. diagnosis of type 2 diabetes mellitus.
boolean
C0011860 (UMLS CUI [1])
Metformin Dose Frequency | Antidiabetics Quantity
Item
2. current treatment with metformin alone (>/= 1500 mg or maximally tolerated dose) or metformin plus 1 other antidiabetic drug. metformin must be administered in twice daily dosing regimen. patients taking metformin three times daily can be included if posology is switched to twice daily and total daily dose is maintained.
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0439603 (UMLS CUI [1,3])
C0935929 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
Glucohemoglobin measurement
Item
3. glycosylated haemoglobin (hba1c) is between 7.0% - 10.0%.
boolean
C0202054 (UMLS CUI [1])
Body mass index
Item
4. body mass index (bmi) </=45 kg/m2.
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Metformin Extended Release
Item
1. treatment with extended release metformin.
boolean
C0025598 (UMLS CUI [1,1])
C1707968 (UMLS CUI [1,2])
Hyperglycemia Uncontrolled | Plasma fasting glucose measurement
Item
2. uncontrolled hyperglycaemia (fasting plasma glucose > 240 mg/dl or 13.3 mmol/l).
boolean
C0020456 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0583513 (UMLS CUI [2])
Myocardial Infarction | Cerebrovascular accident | Transient Ischemic Attack
Item
3. myocardial infarction (mi), stroke or transient ischaemic attack (tia) within 6 months prior to informed consent.
boolean
C0027051 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
C0007787 (UMLS CUI [3])
Liver Dysfunction | Renal Insufficiency | Gastric Bypass
Item
4. impaired hepatic or renal function, or gastric bypass surgery.
boolean
C0086565 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
C0017125 (UMLS CUI [3])
Thiazolidinediones | GLP-1 Mimetics | Anti-Obesity Agents | Insulin
Item
5. treatment with glitazones, glucagon like peptide-1 (glp-1) analogues/mimetics, antiobesity agents, or insulin within 3 months of informed consent.
boolean
C1257987 (UMLS CUI [1])
C3273809 (UMLS CUI [2])
C0376607 (UMLS CUI [3])
C0021641 (UMLS CUI [4])
Systemic steroids | Thyroid Hormones Dosage Change
Item
6. current treatment with systemic steroids or change in dosage of thyroid hormones.
boolean
C2825233 (UMLS CUI [1])
C0040135 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0392747 (UMLS CUI [2,3])
Substance Use Disorders
Item
7. alcohol or drug abuse within 3 months of informed consent.
boolean
C0038586 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
8. participation in another trial with investigational drug within 2 months prior to informed consent.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Premenopausal state | Breast Feeding | Pregnancy | Contraceptive methods Absent
Item
9. pre-menopausal women who are nursing, pregnant or not practicing an acceptable method of birth control.
boolean
C0232969 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032961 (UMLS CUI [3])
C0700589 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial